vimarsana.com
Home
Live Updates
FDA Approves One-Time Gene Therapy Fidanacogene Elaparvovec for Hemophilia B : comparemela.com
FDA Approves One-Time Gene Therapy Fidanacogene Elaparvovec for Hemophilia B
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for certain patients with moderate to severe hemophilia B.
Related Keywords
Adam Cuker ,
Kim Phelan ,
Hemophilia Thrombosis Program ,
Hemophiliab National Organization For Rare Disorders ,
Coalition For Hemophilia ,
Pfizer ,
Penn Comprehensive ,
Updated September ,
Gene Therapy ,
Hemophilia B ,
Fidanacogene Elaparvovec ,
comparemela.com © 2020. All Rights Reserved.